Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults with Uncontrolled Asthma

    Summary
    EudraCT number
    		 2010-020126-17
    Trial protocol
    		 BG  
    Global end of trial date
    15 Aug 2013

    Results information
    Results version number
    		 v1
    This version publication date
    20 Feb 2016
    First version publication date
    20 Feb 2016
    Other versions
    		 v2

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    MI-CP220
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT01238861
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    MedImmune, LLC, an affiliate of AstraZeneca AB
    Sponsor organisation address
    SE-151 85, Sodertalje, Sweden,
    Public contact
    Rene van der Merwe, MBChB, MFPM, Medical Officer, MedImmune, LLC, an affiliate of AstraZeneca AB, vandermerwer@medimmune.com
    Scientific contact
    Rene van der Merwe, MBChB, MFPM, Medical Officer, MedImmune, LLC, an affiliate of AstraZeneca AB, vandermerwer@medimmune.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    15 Aug 2013
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    15 Aug 2013
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this study was to evaluate the effect of multiple-dose subcutaneous (SC) administration of benralizumab on the annual asthma exacerbation rate (AER) in adult participants with uncontrolled, suspected eosinophilic asthma.
    Protection of trial subjects
    The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Participating participant signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    06 Dec 2010
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    		 Safety, Efficacy
    Long term follow-up duration
    		 10 Months
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 74
    Country: Number of subjects enrolled
    Russian Federation: 106
    Country: Number of subjects enrolled
    Brazil: 62
    Country: Number of subjects enrolled
    Bulgaria: 96
    Country: Number of subjects enrolled
    Poland: 61
    Country: Number of subjects enrolled
    Argentina: 70
    Country: Number of subjects enrolled
    Peru: 59
    Country: Number of subjects enrolled
    Mexico: 40
    Country: Number of subjects enrolled
    Canada: 9
    Country: Number of subjects enrolled
    Colombia: 32
    Worldwide total number of subjects
    609
    EEA total number of subjects
    157
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    559
    From 65 to 84 years
    50
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 Participants were stratified based on the protocol defined eosinophilic phenotype (EOS+ versus EOS-) and inhaled corticosteroid (ICS) use during a 3-week screening period. A total of 964 participants were screened out of which 609 were randomized in the study, and of which 606 participants received at least one dose of investigational product.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Eosinophilic phenotype (EOS+) Placebo
    Arm description
    		 EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil’s greater than or equal to 2 percent] positive and/or FeNO [fraction of exhaled nitric oxide] greater than or equal to [>=] 50 parts per billion [ppb]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
    Arm type
    		 Placebo

    Investigational medicinal product name
    Eosinophilic phenotype (EOS+) Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    EOS+ participants received matching placebo injections subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Arm title
    		 EOS+ Benralizumab, 2 mg
    Arm description
    		 EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Benralizumab
    Investigational medicinal product code
    MEDI-563
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.

    Arm title
    		 EOS+ Benralizumab, 20 mg
    Arm description
    		 EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Benralizumab
    Investigational medicinal product code
    MEDI-563
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.

    Arm title
    		 EOS+ Benralizumab, 100 mg
    Arm description
    		 EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Benralizumab
    Investigational medicinal product code
    MEDI-563
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    EOS+ participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Arm title
    		 Non-eosinophil phenotype (EOS-) Placebo
    Arm description
    		 EOS- (defined as ELEN Index negative and FeNO <50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
    Arm type
    		 Placebo

    Investigational medicinal product name
    Non-eosinophil phenotype (EOS-) Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    EOS- (defined as ELEN Index negative and FeNO <50 ppb) participants received matching placebo subcutaneous every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Arm title
    		 EOS- Benralizumab, 100 mg
    Arm description
    		 EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Benralizumab
    Investigational medicinal product code
    MEDI-563
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    EOS- participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Number of subjects in period 1 [1]
    		Eosinophilic phenotype (EOS+) Placebo EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg EOS+ Benralizumab, 100 mg Non-eosinophil phenotype (EOS-) Placebo EOS- Benralizumab, 100 mg
    Started
    80
    81
    81
    82
    142
    140
    Completed
    69
    73
    70
    69
    129
    125
    Not completed
    11
    8
    11
    13
    13
    15
         Did not meet entry ACQ-6 criteria
    -
    -
    1
    -
    1
    1
         Personal problems
    -
    -
    -
    1
    -
    -
         Subject moved out of state/area
    -
    -
    1
    1
    -
    -
         Lack of compliance
    -
    -
    -
    -
    -
    1
         Strongyloides stercoralis antibodies +
    -
    -
    -
    1
    -
    -
         Unplanned surgery
    1
    -
    -
    -
    -
    -
         Unable to continue visits
    -
    -
    -
    1
    -
    1
         Consent withdrawn by subject
    6
    5
    4
    8
    10
    9
         Adverse event, non-fatal
    -
    1
    -
    -
    -
    -
         Subject traveled to Argentina by 1 year
    -
    -
    1
    -
    -
    -
         Incorrect enrollment/randomization
    -
    -
    1
    -
    1
    -
         Serious adverse event
    -
    -
    -
    -
    -
    1
         Lost to follow-up
    4
    2
    3
    1
    1
    2
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: Not all randomized subjects were treated with study drugs. Hence, the worldwide number enrolled in the trial, which is the same as the number randomized, differs from the number of subjects reported in the baseline period.

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Eosinophilic phenotype (EOS+) Placebo
    Reporting group description
    		 EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil’s greater than or equal to 2 percent] positive and/or FeNO [fraction of exhaled nitric oxide] greater than or equal to [>=] 50 parts per billion [ppb]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Reporting group title
    EOS+ Benralizumab, 2 mg
    Reporting group description
    		 EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Reporting group title
    EOS+ Benralizumab, 20 mg
    Reporting group description
    		 EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Reporting group title
    EOS+ Benralizumab, 100 mg
    Reporting group description
    		 EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Reporting group title
    Non-eosinophil phenotype (EOS-) Placebo
    Reporting group description
    		 EOS- (defined as ELEN Index negative and FeNO <50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Reporting group title
    EOS- Benralizumab, 100 mg
    Reporting group description
    		 EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Reporting group values
    		 Eosinophilic phenotype (EOS+) Placebo EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg EOS+ Benralizumab, 100 mg Non-eosinophil phenotype (EOS-) Placebo EOS- Benralizumab, 100 mg Total
    Number of subjects
    		 80 81 81 82 142 140 606
    Age categorical
    Units: Subjects
    Age Continuous |
    Units: years
        arithmetic mean (standard deviation)
    		 45.6 ( 11.7 ) 47.1 ( 12.8 ) 46.6 ( 13.2 ) 47.8 ( 12.9 ) 50 ( 12.3 ) 50 ( 11.5 ) -
    Gender, Male/Female
    Units: participants
        Female
    		 53 58 48 60 100 98 417
        Male
    		 27 23 33 22 42 42 189

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Eosinophilic phenotype (EOS+) Placebo
    Reporting group description
    		 EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil’s greater than or equal to 2 percent] positive and/or FeNO [fraction of exhaled nitric oxide] greater than or equal to [>=] 50 parts per billion [ppb]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Reporting group title
    EOS+ Benralizumab, 2 mg
    Reporting group description
    		 EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Reporting group title
    EOS+ Benralizumab, 20 mg
    Reporting group description
    		 EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Reporting group title
    EOS+ Benralizumab, 100 mg
    Reporting group description
    		 EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Reporting group title
    Non-eosinophil phenotype (EOS-) Placebo
    Reporting group description
    		 EOS- (defined as ELEN Index negative and FeNO <50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Reporting group title
    EOS- Benralizumab, 100 mg
    Reporting group description
    		 EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Subject analysis set title
    EOS+ Placebo - Safety population
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    EOS+ participants received two placebo injections subcutaneously.

    Subject analysis set title
    EOS- Placebo - Safety population
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    EOS- participants received two placebo injections subcutaneously.

    Subject analysis set title
    EOS- Placebo - mITT Population
    Subject analysis set type
    		 Modified intention-to-treat
    Subject analysis set description
    EOS- participants received two placebo injections subcutaneously.

    Subject analysis set title
    Benralizumab (100 mg) - mITT Population
    Subject analysis set type
    		 Modified intention-to-treat
    Subject analysis set description
    EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.The modified intent-to-treat (mITT) population included all randomized participants who received any dose of investigational product.

    Subject analysis set title
    Placebo - mITT population
    Subject analysis set type
    		 Modified intention-to-treat
    Subject analysis set description
    Participants received two placebo injections subcutaneously.

    Subject analysis set title
    EOS- Benralizumab, 100 mg - Safety Population
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.

    Subject analysis set title
    Benralizumab, 100 mg - PK Population
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.he Pharmacokinetic (PK) Population included all participants who received at least one dose of benralizumab and had at least one quantifiable PK observation. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for PK in the 100 mg benralizumab group.

    Primary: Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants

    		 Close Top of page
    End point title
    		 Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants [1]
    End point description
    The annual asthma exacerbation rate (AER) was calculated as the total number of observed exacerbations in each group up to week 52, divided by total duration of person-year follow-up in each group. An asthma exacerbation is defined as a progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 days as outlined in the Asthma Action Plan provided to the participant by the investigator on Day 1. The modified intent-to-treat (mITT) population included all randomized participants who received any dose of investigational product.
    End point type
    Primary
    End point timeframe
    Week 1 up to Week 52
    Notes
    [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 Eosinophilic phenotype (EOS+) Placebo EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg EOS+ Benralizumab, 100 mg
    Number of subjects analysed
    80
    81
    81
    82
    Units: AER events/person-year
        number (not applicable)
    0.57
    0.65
    0.37
    0.34
    Statistical analysis title
    		 Statistical Analysis-1
    Comparison groups
    Eosinophilic phenotype (EOS+) Placebo v EOS+ Benralizumab, 2 mg
    Number of subjects included in analysis
    161
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.781
    Method
    		 Poisson Regression Method
    Parameter type
    		 Rate Ratio
    Point estimate
    1.09
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 0.74
         upper limit
    		 1.59
    Statistical analysis title
    		 Statistical Analysis-3
    Comparison groups
    Eosinophilic phenotype (EOS+) Placebo v EOS+ Benralizumab, 100 mg
    Number of subjects included in analysis
    162
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.096
    Method
    		 Poisson Regression Method
    Parameter type
    		 Rate ratio
    Point estimate
    0.59
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 0.4
         upper limit
    		 0.89
    Statistical analysis title
    		 Statistical Analysis-2
    Comparison groups
    Eosinophilic phenotype (EOS+) Placebo v EOS+ Benralizumab, 20 mg
    Number of subjects included in analysis
    161
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.173
    Method
    		 Poisson Regression Method
    Parameter type
    		 Rate Ratio
    Point estimate
    0.64
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 0.42
         upper limit
    		 0.97

    Secondary: Dose Response in EOS+ Participants

    		 Close Top of page
    End point title
    		 Dose Response in EOS+ Participants [2]
    End point description
    Due to change in planned analysis after unblinding of study data, dose response was not performed.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 66
    Notes
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 Eosinophilic phenotype (EOS+) Placebo EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg EOS+ Benralizumab, 100 mg
    Number of subjects analysed
    0 [3]
    0 [4]
    0 [5]
    0 [6]
    Units: participants
    Notes
    [3] - Due to change in planned analysis, dose response was not analyzed.
    [4] - Due to change in planned analysis, dose response was not analyzed.
    [5] - Due to change in planned analysis, dose response was not analyzed.
    [6] - Due to change in planned analysis, dose response was not analyzed.
    No statistical analyses for this end point

    Secondary: Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss)

    		 Close Top of page
    End point title
    		 Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss) [7]
    End point description
    The Pharmacokinetic (PK) Population included all participants who received at least one dose of benralizumab and had at least one quantifiable PK observation. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for PK in the 100 mg benralizumab group.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4, 16, 24, 32, 40, and 52
    Notes
    [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab, 100 mg - PK Population
    Number of subjects analysed
    81
    81
    223
    Units: microgram per milliliter
        arithmetic mean (standard deviation)
    34.7 ( 131 )
    182 ( 180 )
    869 ( 665 )
    No statistical analyses for this end point

    Secondary: Dose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD)

    		 Close Top of page
    End point title
    		 Dose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD) [8]
    End point description
    The PK Population included all participants who received at least one dose of benralizumab and had at least one quantifiable PK observation. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for PK in the 100 mg benralizumab group.
    End point type
    Secondary
    End point timeframe
    Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4, 16, 24, 32, 40, and 52
    Notes
    [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab, 100 mg - PK Population
    Number of subjects analysed
    81
    81
    223
    Units: microgram per milliliter
        arithmetic mean (standard deviation)
    17.3 ( 65.3 )
    9.1 ( 9.02 )
    8.69 ( 6.65 )
    No statistical analyses for this end point

    Secondary: Percentage of Participants with Anti-Drug Antibodies (ADA) to Benralizumab

    		 Close Top of page
    End point title
    		 Percentage of Participants with Anti-Drug Antibodies (ADA) to Benralizumab [9]
    End point description
    Immunogenicity assessment included determination of anti-drug (benralizumab) antibodies in serum samples. ADA positive was defined as a titer >=50 at any point in the study. It was observed at baseline and any visit during the study. The mITT population included all randomized participants who received any dose of investigational product.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 92
    Notes
    [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg EOS+ Benralizumab, 100 mg EOS+ Placebo - Safety population
    Number of subjects analysed
    81
    81
    82
    80
    Units: percentage of participants
        number (not applicable)
    42
    30.9
    25.6
    3.8
    No statistical analyses for this end point

    Secondary: Change from Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52

    		 Close Top of page
    End point title
    		 Change from Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52 [10]
    End point description
    Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. ACQ-6 score was summarized together for all participants. The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 52
    Notes
    [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 Eosinophilic phenotype (EOS+) Placebo EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg EOS+ Benralizumab, 100 mg
    Number of subjects analysed
    80
    81
    81
    82
    Units: units on a scale
    arithmetic mean (standard deviation)
        Baseline (n=80,80,80,82,142,140)
    2.7479 ( 0.9762 )
    2.6479 ( 0.9908 )
    2.475 ( 0.9106 )
    2.5346 ( 0.9728 )
        Change at Week 52 (n=34,42,40,39,64,73)
    -0.8922 ( 1.1969 )
    -1.1032 ( 1.1207 )
    -1.25 ( 1.2247 )
    -1.1239 ( 1.2852 )
    Statistical analysis title
    		 Statistical Analysis-1
    Comparison groups
    Eosinophilic phenotype (EOS+) Placebo v EOS+ Benralizumab, 2 mg
    Number of subjects included in analysis
    161
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.125
    Method
    		 ANCOVA
    Confidence interval
    Statistical analysis title
    		 Statistical Analysis-3
    Comparison groups
    Eosinophilic phenotype (EOS+) Placebo v EOS+ Benralizumab, 100 mg
    Number of subjects included in analysis
    162
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.057
    Method
    		 ANCOVA
    Confidence interval
    Statistical analysis title
    		 Statistical Analysis-2
    Comparison groups
    Eosinophilic phenotype (EOS+) Placebo v EOS+ Benralizumab, 20 mg
    Number of subjects included in analysis
    161
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.074
    Method
    		 ANCOVA
    Confidence interval

    Secondary: Change From Baseline in Mean Total Nasal Symptoms Score (TNSS) at Week 52

    		 Close Top of page
    End point title
    		 Change From Baseline in Mean Total Nasal Symptoms Score (TNSS) at Week 52 [11]
    End point description
    Total Nasal Symptoms Score (TNSS) is a 3-item questionnaire, the sum of nasal symptoms, namely, nasal obstruction (rhinorrhea), nasal congestion, and nasal itching/sneezing. Each symptom was rated on a scale from 0-3, with 0 representing no symptoms, 1 mild, 2 moderate, and 3 severe symptoms. TNSS score was a summation of the 3 individual nasal symptom. TNSS score could range from 0 to 9 where higher score indicates worsening. Data was summarized by each treatment group. In addition, data was summarized together for “EOS+ and EOS- Placebo” arms and “EOS+ and EOS- benralizumab 100 mg” arms. The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 52
    Notes
    [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab (100 mg) - mITT Population Placebo - mITT population
    Number of subjects analysed
    81
    81
    222
    222
    Units: units on a scale
    arithmetic mean (standard deviation)
        Baseline (n=71,27,25,81))
    4.8 ( 2 )
    5.3 ( 1.8 )
    4.4 ( 2.1 )
    4.3 ( 2 )
        Change at Week 52 (n=89,39,39,106)
    -0.8 ( 2.01 )
    -1 ( 2.96 )
    -0.8 ( 2.24 )
    -0.4 ( 2.9 )
    No statistical analyses for this end point

    Secondary: Change from baseline in Mean Asthma Symptom Diary Score at Week 51-52

    		 Close Top of page
    End point title
    		 Change from baseline in Mean Asthma Symptom Diary Score at Week 51-52 [12]
    End point description
    Asthma Symptom Diary included 7 questions about the participant symptom and the overall impact of treatment on the disease during the study period. Mean scores of the 7 questions were calculated to identify asthma symptom-free days. Asthma Symptom Diary Scores were analyzed on a bi-weekly basis and compared to baseline scores. Overall symptom score=(daytime frequency score + daytime severity score + nighttime severity score)/3, where total score ranges from 0 to 9. Higher score represents worsening. Mean asthma symptom diary score were summarized together for all participants. Data was summarized by each treatment group. In addition, data was summarized together for “EOS+ and EOS- Placebo” arms and “EOS+ and EOS- benralizumab 100 mg” arms. The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 51-52
    Notes
    [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab (100 mg) - mITT Population Placebo - mITT population
    Number of subjects analysed
    81
    81
    222
    222
    Units: units on a scale
    arithmetic mean (standard deviation)
        Baseline (n=204,72,74,210)
    1.65 ( 0.65 )
    1.6 ( 0.61 )
    1.6 ( 0.62 )
    1.58 ( 0.6 )
        Change at Week 51-52 (n=111,36,39,111)
    -0.56 ( 0.76 )
    -0.56 ( 0.69 )
    -0.53 ( 0.67 )
    -0.37 ( 0.61 )
    Statistical analysis title
    		 Statistical Analysis-1
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.131
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    -0.182
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.336
         upper limit
    		 -0.028
    Statistical analysis title
    		 Statistical Analysis-3
    Comparison groups
    Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    444
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.097
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    -0.14
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.247
         upper limit
    		 -0.032
    Statistical analysis title
    		 Statistical Analysis-2
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.126
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    -0.173
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.317
         upper limit
    		 -0.028

    Secondary: Change from Baseline in Rescue Medication Use at Week 51-52

    		 Close Top of page
    End point title
    		 Change from Baseline in Rescue Medication Use at Week 51-52 [13]
    End point description
    Participants were provided inhalers of the same dose (medium- or high-dose) inhaled corticosteroid (ICS) plus long-acting beta antagonist (LABA) combination product as baseline prophylactic medication and continued with same dose throughout the study. Rescue medications such as short-term beta2 agonists were used as first-line treatment for worsening asthma symptoms. Investigator prescribed additional short term asthma controller medications included additional ICS, theophylline, inhaled cromones or antimuscarinics; if asthma symptoms remained mild but not resolved. If asthma symptoms worsened, received an oral corticosteroid burst. All rescue medications use with prophylactic medication (+ prophylactic) and without prophylactic medication (- prophylactic) was recorded in asthma symptom dairy and analyzed on a bi-weekly basis and compared to baseline scores. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 51-52
    Notes
    [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab (100 mg) - mITT Population Placebo - mITT population
    Number of subjects analysed
    81 [14]
    81 [15]
    222 [16]
    222 [17]
    Units: rescue medication per 2 weeks
    arithmetic mean (standard deviation)
        Baseline without prophylactic (n=204,72,74,210)
    3.57 ( 3.67 )
    3.82 ( 4.34 )
    3.16 ( 2.82 )
    3.09 ( 2.55 )
        Baseline with prophylactic (n=204,72,74,210)
    4.71 ( 5.56 )
    5.24 ( 6.4 )
    4.22 ( 3.9 )
    4.07 ( 3.34 )
        Change Week 51-52 -prophylactic(n=111,36,39,111)
    -1.4116 ( 2.8722 )
    -1.8804 ( 5.3129 )
    -1.1589 ( 2.0086 )
    -1.254 ( 2.4571 )
        Change Week 51-52 +prophylactic(n=111,36,39,111)
    -1.681 ( 4.2247 )
    -2.5118 ( 7.6814 )
    -1.4693 ( 2.5603 )
    -1.6855 ( 3.2875 )
    Notes
    [14] - mITT population
    [15] - mITT population
    [16] - mITT population
    [17] - mITT population
    Statistical analysis title
    		 Statistical Analysis-1
    Statistical analysis description
    Analysis reported for rescue medication use without prophylactic at Week 51-52.
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.642
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    -0.174
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.654
         upper limit
    		 0.306
    Statistical analysis title
    		 Statistical Analysis-2
    Statistical analysis description
    Analysis reported for rescue medication use without prophylactic at Week 51-52.
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.824
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.111
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.533
         upper limit
    		 0.756
    Statistical analysis title
    		 Statistical Analysis-3
    Statistical analysis description
    Analysis reported for rescue medication use without prophylactic at Week 51-52.
    Comparison groups
    Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    444
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.91
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.029
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.297
         upper limit
    		 0.355
    Statistical analysis title
    		 Statistical Analysis-4
    Statistical analysis description
    Analysis reported for rescue medication use with prophylactic at Week 51-52.
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.992
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    -0.004
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.602
         upper limit
    		 0.593
    Statistical analysis title
    		 Statistical Analysis-5
    Statistical analysis description
    Analysis reported for rescue medication use with prophylactic at Week 51-52.
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.624
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.337
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.548
         upper limit
    		 1.222
    Statistical analysis title
    		 Statistical Analysis-6
    Statistical analysis description
    Analysis reported for rescue medication use with prophylactic at Week 51-52.
    Comparison groups
    Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    444
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.645
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.15
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.267
         upper limit
    		 0.567

    Secondary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52

    		 Close Top of page
    End point title
    		 Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 [18]
    End point description
    FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data was summarized by each treatment group. In addition, data was summarized together for “EOS+ and EOS- Placebo” arms and “EOS+ and EOS- benralizumab 100 mg” arms. The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 52
    Notes
    [18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab (100 mg) - mITT Population Placebo - mITT population
    Number of subjects analysed
    81
    81
    222
    222
    Units: liters
    arithmetic mean (standard deviation)
        Baseline (n=215,80,81,218)
    1.978 ( 0.701 )
    2.08 ( 0.751 )
    2.012 ( 0.672 )
    2.033 ( 0.669 )
        Change at Week 52 (n=150,51,58,160)
    0.1631 ( 0.4691 )
    0.1847 ( 0.5234 )
    0.0998 ( 0.3541 )
    0.0098 ( 0.3615 )
    Statistical analysis title
    		 Statistical Analysis-1
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.014
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.157
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 0.076
         upper limit
    		 0.237
    Statistical analysis title
    		 Statistical Analysis-2
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.004
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.184
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 0.102
         upper limit
    		 0.266
    Statistical analysis title
    		 Statistical Analysis-3
    Comparison groups
    Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    444
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.026
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.091
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 0.039
         upper limit
    		 0.143

    Secondary: Change From Baseline in Mean Forced Vital Capacity (FVC) at Week 52

    		 Close Top of page
    End point title
    		 Change From Baseline in Mean Forced Vital Capacity (FVC) at Week 52 [19]
    End point description
    Forced Vital Capacity (FVC) was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 52
    Notes
    [19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg EOS+ Benralizumab, 100 mg EOS+ Placebo - Safety population
    Number of subjects analysed
    81
    81
    82
    80
    Units: liters
    arithmetic mean (standard deviation)
        Baseline (n=80,80,81,82,135,136)
    3.069 ( 0.957 )
    3.285 ( 1.028 )
    3.11 ( 0.851 )
    3.282 ( 1.03 )
        Change at Week 52 (n=51,51,58,59,99,101)
    0.129 ( 0.565 )
    0.19 ( 0.586 )
    0.166 ( 0.445 )
    0.029 ( 0.514 )
    Statistical analysis title
    		 Statistical Analysis-1
    Comparison groups
    EOS+ Benralizumab, 20 mg v EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 100 mg v EOS+ Placebo - Safety population
    Number of subjects included in analysis
    324
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.384
    Method
    		 ANCOVA
    Confidence interval
    Statistical analysis title
    		 Statistical Analysis-3
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v EOS+ Benralizumab, 100 mg v EOS+ Placebo - Safety population
    Number of subjects included in analysis
    324
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.134
    Method
    		 ANCOVA
    Confidence interval
    Statistical analysis title
    		 Statistical Analysis-2
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v EOS+ Benralizumab, 100 mg v EOS+ Placebo - Safety population
    Number of subjects included in analysis
    324
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.092
    Method
    		 ANCOVA
    Confidence interval

    Secondary: Change From Baseline in Peak Expiratory Flow (PEF) at Week 52

    		 Close Top of page
    End point title
    		 Change From Baseline in Peak Expiratory Flow (PEF) at Week 52 [20]
    End point description
    The PEF is a participant’s maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed while sitting or standing prior to using any medication (if needed) for asthma. Home PEF was summarized separately for morning and evening assessments. Data was summarized by each treatment group. In addition, data was summarized together for “EOS+ and EOS- Placebo” arms and “EOS+ and EOS- benralizumab 100 mg” arms. The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 52
    Notes
    [20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab (100 mg) - mITT Population Placebo - mITT population
    Number of subjects analysed
    81
    81
    222
    222
    Units: liters per minute
    arithmetic mean (standard deviation)
        Baseline (n=215,80,81,218)
    325.5 ( 101.6 )
    323.1 ( 100.8 )
    323.8 ( 101.7 )
    319.3 ( 104.7 )
        Change at Week 52 (n=150,51,58,160)
    29 ( 64.1 )
    45.9 ( 95.5 )
    26.6 ( 66.3 )
    13 ( 64.6 )
    No statistical analyses for this end point

    Secondary: Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Score at Week 52

    		 Close Top of page
    End point title
    		 Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Score at Week 52 [21]
    End point description
    AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment) and mean response was calculated as overall score. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). The AQLQ(S) responses were categorized as improvement (defined as change from baseline >=0.5), no change (defined as change from baseline >= -0.5 to < 0.5), and worse (defined as change from baseline < -0.5). Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 52
    Notes
    [21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab (100 mg) - mITT Population Placebo - mITT population
    Number of subjects analysed
    81 [22]
    81 [23]
    222 [24]
    222 [25]
    Units: units on a scale
    arithmetic mean (standard deviation)
        Baseline (n=214,78,80,217)
    3.72 ( 1.17 )
    3.79 ( 1.06 )
    3.72 ( 1.01 )
    3.72 ( 1.04 )
        Change at Week 52 (n=88,39,38,105)
    1.2612 ( 1.2082 )
    1.4474 ( 1.4262 )
    1.1223 ( 1.2636 )
    0.9634 ( 1.3342 )
    Notes
    [22] - mITT population
    [23] - mITT population
    [24] - mITT population
    [25] - mITT population
    Statistical analysis title
    		 Statistical Analysis-1
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.069
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.404
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 0.121
         upper limit
    		 0.687
    Statistical analysis title
    		 Statistical Analysis-2
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.049
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.462
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 0.163
         upper limit
    		 0.761
    Statistical analysis title
    		 Statistical Analysis-3
    Comparison groups
    Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    444
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.168
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.238
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 0.017
         upper limit
    		 0.459

    Secondary: Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D) Health State Evaluation at Week 52

    		 Close Top of page
    End point title
    		 Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D) Health State Evaluation at Week 52 [26]
    End point description
    The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems). Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Data was summarized by each treatment group. In addition, data was summarized together for “EOS+ and EOS- Placebo” arms and “EOS+ and EOS- benralizumab 100 mg” arms. The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 52
    Notes
    [26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab (100 mg) - mITT Population Placebo - mITT population
    Number of subjects analysed
    81
    81
    222
    222
    Units: units on a scale
    arithmetic mean (standard deviation)
        Baseline (n=213,79,74,209)
    0.7418 ( 0.2376 )
    0.7877 ( 0.1878 )
    0.7679 ( 0.1623 )
    0.7629 ( 0.2153 )
        Change at Week 52 (n=148,58,53,161)
    0.0822 ( 0.3137 )
    0.1223 ( 0.2132 )
    0.0824 ( 0.2179 )
    0.0853 ( 0.2096 )
    Statistical analysis title
    		 Statistical Analysis-1
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.51
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    -0.02
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.058
         upper limit
    		 0.019
    Statistical analysis title
    		 Statistical Analysis-3
    Comparison groups
    Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    444
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.599
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.011
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.016
         upper limit
    		 0.038
    Statistical analysis title
    		 Statistical Analysis-2
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.113
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.041
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 0.008
         upper limit
    		 0.074

    Secondary: Change From Baseline in EQ-5D Visual Analog Scale (VAS) at Week 52

    		 Close Top of page
    End point title
    		 Change From Baseline in EQ-5D Visual Analog Scale (VAS) at Week 52 [27]
    End point description
    The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data was summarized by each treatment group. In addition, data was summarized together for “EOS+ and EOS- Placebo” arms and “EOS+ and EOS- benralizumab 100 mg” arms. The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 52
    Notes
    [27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab (100 mg) - mITT Population Placebo - mITT population
    Number of subjects analysed
    81
    81
    222
    222
    Units: units on a scale
    arithmetic mean (standard deviation)
        Baseline (n=213,79,74,208)
    65.4937 ( 18.5063 )
    64.3378 ( 18.1427 )
    64.625 ( 19.7778 )
    65.0798 ( 17.8903 )
        Change at Week 52 (n=148,58,53,161)
    12.5517 ( 20.8008 )
    15.4906 ( 21.7297 )
    13.7391 ( 20.5139 )
    12.8041 ( 19.1036 )
    Statistical analysis title
    		 Statistical Analysis-1
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.871
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    -0.373
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -3.333
         upper limit
    		 2.586
    Statistical analysis title
    		 Statistical Analysis-3
    Comparison groups
    Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    444
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.503
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    1.139
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -1.041
         upper limit
    		 3.319
    Statistical analysis title
    		 Statistical Analysis-2
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.227
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    2.857
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.175
         upper limit
    		 5.889

    Secondary: Change From Baseline in Percentage of Nocturnal Awakening-Free Nights at Week 51-52

    		 Close Top of page
    End point title
    		 Change From Baseline in Percentage of Nocturnal Awakening-Free Nights at Week 51-52 [28]
    End point description
    Percentage of nocturnal awakening-free nights were analyzed on a bi-weekly basis and compared to baseline scores. Data was summarized by each treatment group. In addition, data was summarized together for “EOS+ and EOS- Placebo” arms and “EOS+ and EOS- benralizumab 100 mg” arms.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 51-52
    Notes
    [28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab (100 mg) - mITT Population Placebo - mITT population
    Number of subjects analysed
    81
    81
    222
    222
    Units: percent nocturnal awakening-free nights
    arithmetic mean (standard deviation)
        Baseline (n=204,72,74,210)
    45.07 ( 40.04 )
    51.57 ( 39.72 )
    50.92 ( 37.72 )
    52.05 ( 36.96 )
        Change at Week 51-52 (n=111,36,39,111)
    27.1749 ( 41.7342 )
    29.6181 ( 38.4315 )
    23.3054 ( 36.2761 )
    19.7595 ( 39.1388 )
    Statistical analysis title
    		 Statistical analysis 1
    Statistical analysis description
    Placebo, EOS+ Benralizumab, 2 mg
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.55 [29]
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    3.907
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -4.483
         upper limit
    		 12.297
    Notes
    [29] - P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
    Statistical analysis title
    		 Statistical analysis 3
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.413 [30]
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    3.54
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -2.006
         upper limit
    		 9.086
    Notes
    [30] - P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
    Statistical analysis title
    		 Statistical analysis 2
    Statistical analysis description
    Placebo, EOS+ Benralizumab, 20 mg
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.215 [31]
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    7.659
    Confidence interval
         level
    		 80%
         sides
    2-sided
         lower limit
    		 -0.262
         upper limit
    		 15.579
    Notes
    [31] - P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.

    Secondary: Change From Baseline in Mean Fraction Exhaled Nitric Oxide (FeNO) at Week 52

    		 Close Top of page
    End point title
    		 Change From Baseline in Mean Fraction Exhaled Nitric Oxide (FeNO) at Week 52 [32]
    End point description
    Data was summarized by each treatment group. In addition, data was summarized together for “EOS+ and EOS- Placebo” arms and “EOS+ and EOS- benralizumab 100 mg” arms.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 52
    Notes
    [32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The EOS- participants were only for exploratory analyses, and hence, data was reported for EOS+ participants in this endpoint.
    End point values
    		 EOS+ Benralizumab, 2 mg EOS+ Benralizumab, 20 mg Benralizumab (100 mg) - mITT Population Placebo - mITT population
    Number of subjects analysed
    81
    81
    222
    222
    Units: parts per billion
    arithmetic mean (standard deviation)
        Baseline (n=222,81,81,222)
    39.52 ( 32.67 )
    40.79 ( 31.03 )
    26.68 ( 23.1 )
    26.88 ( 23.57 )
        Change at Week 52 (n=148,57,56,157)
    -3.2222 ( 33.2543 )
    -6.1905 ( 30.1103 )
    1.4384 ( 28.909 )
    1.2523 ( 16.02 )
    Statistical analysis title
    		 Statistical analysis 1
    Statistical analysis description
    Placebo, EOS+ Benralizumab, 2 mg
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.896 [33]
    Method
    		 ANCOVA
    Confidence interval
    Notes
    [33] - P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
    Statistical analysis title
    		 Statistical analysis 2
    Statistical analysis description
    Placebo, EOS+ Benralizumab, 20 mg
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.944 [34]
    Method
    		 ANCOVA
    Confidence interval
    Notes
    [34] - P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.
    Statistical analysis title
    		 Statistical analysis 3
    Statistical analysis description
    Placebo, Benralizumab (100 mg)
    Comparison groups
    EOS+ Benralizumab, 2 mg v EOS+ Benralizumab, 20 mg v Placebo - mITT population v Benralizumab (100 mg) - mITT Population
    Number of subjects included in analysis
    606
    Analysis specification
    Pre-specified
    Analysis type
    		 other
    P-value
    		 = 0.667 [35]
    Method
    		 ANCOVA
    Confidence interval
    Notes
    [35] - P-value was calculated by ANCOVA with treatment, baseline inhaled steroid status and baseline observed value as covariates.

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From initiation of investigational product administration up to Week 92
    Adverse event reporting additional description
    The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    16.0
    Reporting groups
    Reporting group title
    EOS POS Placebo
    Reporting group description
    		 EOS+ participants received two placebo injections subcutaneously.

    Reporting group title
    EOS POS Benralizumab 2 mg
    Reporting group description
    		 EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.

    Reporting group title
    EOS POS Benralizumab 20 mg
    Reporting group description
    		 EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.

    Reporting group title
    EOS POS Benralizumab 100 mg
    Reporting group description
    		 EOS+ participants received two benralizumab 50 mg injections subcutaneously.

    Reporting group title
    EOS NEG Placebo
    Reporting group description
    		 EOS- participants received two placebo injections subcutaneously.

    Reporting group title
    EOS NEG Benralizumab 100 mg
    Reporting group description
    		 EOS- participants received two benralizumab 50 mg injections subcutaneously.

    Serious adverse events
    		 EOS POS Placebo EOS POS Benralizumab 2 mg EOS POS Benralizumab 20 mg EOS POS Benralizumab 100 mg EOS NEG Placebo EOS NEG Benralizumab 100 mg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    7 / 80 (8.75%)
    10 / 81 (12.35%)
    6 / 81 (7.41%)
    6 / 82 (7.32%)
    16 / 141 (11.35%)
    18 / 141 (12.77%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Fibrous histiocytoma
         subjects affected / exposed
    1 / 80 (1.25%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Malignant melanoma
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thyroid neoplasm
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    1 / 81 (1.23%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Uterine leiomyoma
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    1 / 81 (1.23%)
    1 / 82 (1.22%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Hypertension
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    1 / 82 (1.22%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Polyarteritis nodosa
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    1 / 82 (1.22%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anaphylactic reaction
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    2 / 80 (2.50%)
    2 / 81 (2.47%)
    0 / 81 (0.00%)
    2 / 82 (2.44%)
    8 / 141 (5.67%)
    5 / 141 (3.55%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 0
    0 / 3
    0 / 14
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asthmatic crisis
         subjects affected / exposed
    1 / 80 (1.25%)
    0 / 81 (0.00%)
    1 / 81 (1.23%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nasal polyps
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    1 / 82 (1.22%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Interstitial lung diseas
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Depression
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Insomnia
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Abdominal wound dehiscen
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ulna fracture
         subjects affected / exposed
    0 / 80 (0.00%)
    1 / 81 (1.23%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Acute myocardial infarct
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    1 / 81 (1.23%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure acute
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myocardial ischaemia
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    2 / 81 (2.47%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Supraventricular tachyca
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Convulsion
         subjects affected / exposed
    0 / 80 (0.00%)
    1 / 81 (1.23%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Grand mal convulsion
         subjects affected / exposed
    0 / 80 (0.00%)
    1 / 81 (1.23%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    1 / 80 (1.25%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal hernia
         subjects affected / exposed
    1 / 80 (1.25%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    1 / 80 (1.25%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    1 / 82 (1.22%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrooesophageal reflux
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Umbilical hernia
         subjects affected / exposed
    1 / 80 (1.25%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholecystitis
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis acute
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Erythema nodosum
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    1 / 81 (1.23%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urticaria
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eczema
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    0 / 80 (0.00%)
    2 / 81 (2.47%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal pain
         subjects affected / exposed
    0 / 80 (0.00%)
    1 / 81 (1.23%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteochondrosis
         subjects affected / exposed
    0 / 80 (0.00%)
    1 / 81 (1.23%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal osteoarthritis
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis infective
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eczema infected
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enteritis infectious
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastritis viral
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    1 / 82 (1.22%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Herpes zoster
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 80 (0.00%)
    1 / 81 (1.23%)
    0 / 81 (0.00%)
    1 / 82 (1.22%)
    1 / 141 (0.71%)
    3 / 141 (2.13%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    1 / 2
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    1 / 141 (0.71%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower respiratory tract
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    1 / 141 (0.71%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Post procedural cellulit
         subjects affected / exposed
    0 / 80 (0.00%)
    1 / 81 (1.23%)
    0 / 81 (0.00%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Postoperative wound infe
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    1 / 82 (1.22%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tonsillitis bacterial
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    0 / 81 (0.00%)
    1 / 82 (1.22%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hypercholesterolaemia
         subjects affected / exposed
    0 / 80 (0.00%)
    0 / 81 (0.00%)
    1 / 81 (1.23%)
    0 / 82 (0.00%)
    0 / 141 (0.00%)
    0 / 141 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 2%
    Non-serious adverse events
    		 EOS POS Placebo EOS POS Benralizumab 2 mg EOS POS Benralizumab 20 mg EOS POS Benralizumab 100 mg EOS NEG Placebo EOS NEG Benralizumab 100 mg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    44 / 80 (55.00%)
    54 / 81 (66.67%)
    57 / 81 (70.37%)
    68 / 82 (82.93%)
    94 / 141 (66.67%)
    93 / 141 (65.96%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    1 / 80 (1.25%)
    3 / 81 (3.70%)
    0 / 81 (0.00%)
    3 / 82 (3.66%)
    4 / 141 (2.84%)
    10 / 141 (7.09%)
         occurrences all number
    2
    3
    0
    3
    4
    12
    Nervous system disorders
    Headache
         subjects affected / exposed
    8 / 80 (10.00%)
    8 / 81 (9.88%)
    6 / 81 (7.41%)
    9 / 82 (10.98%)
    8 / 141 (5.67%)
    13 / 141 (9.22%)
         occurrences all number
    13
    13
    10
    10
    9
    17
    General disorders and administration site conditions
    Injection site erythema
         subjects affected / exposed
    0 / 80 (0.00%)
    2 / 81 (2.47%)
    2 / 81 (2.47%)
    8 / 82 (9.76%)
    0 / 141 (0.00%)
    10 / 141 (7.09%)
         occurrences all number
    0
    2
    4
    17
    0
    17
    Injection site pain
         subjects affected / exposed
    0 / 80 (0.00%)
    6 / 81 (7.41%)
    4 / 81 (4.94%)
    2 / 82 (2.44%)
    6 / 141 (4.26%)
    2 / 141 (1.42%)
         occurrences all number
    0
    6
    17
    3
    12
    4
    Pyrexia
         subjects affected / exposed
    1 / 80 (1.25%)
    4 / 81 (4.94%)
    3 / 81 (3.70%)
    1 / 82 (1.22%)
    1 / 141 (0.71%)
    2 / 141 (1.42%)
         occurrences all number
    1
    4
    3
    1
    1
    2
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    2 / 80 (2.50%)
    3 / 81 (3.70%)
    2 / 81 (2.47%)
    1 / 82 (1.22%)
    2 / 141 (1.42%)
    2 / 141 (1.42%)
         occurrences all number
    3
    3
    2
    1
    2
    2
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    30 / 80 (37.50%)
    28 / 81 (34.57%)
    24 / 81 (29.63%)
    26 / 82 (31.71%)
    42 / 141 (29.79%)
    42 / 141 (29.79%)
         occurrences all number
    51
    59
    42
    36
    67
    77
    Rhinitis allergic
         subjects affected / exposed
    3 / 80 (3.75%)
    3 / 81 (3.70%)
    8 / 81 (9.88%)
    6 / 82 (7.32%)
    4 / 141 (2.84%)
    5 / 141 (3.55%)
         occurrences all number
    3
    5
    13
    8
    8
    11
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    1 / 80 (1.25%)
    4 / 81 (4.94%)
    5 / 81 (6.17%)
    3 / 82 (3.66%)
    1 / 141 (0.71%)
    3 / 141 (2.13%)
         occurrences all number
    1
    5
    6
    3
    1
    3
    Back pain
         subjects affected / exposed
    3 / 80 (3.75%)
    4 / 81 (4.94%)
    2 / 81 (2.47%)
    2 / 82 (2.44%)
    1 / 141 (0.71%)
    3 / 141 (2.13%)
         occurrences all number
    3
    4
    2
    4
    1
    3
    Myalgia
         subjects affected / exposed
    1 / 80 (1.25%)
    2 / 81 (2.47%)
    3 / 81 (3.70%)
    2 / 82 (2.44%)
    1 / 141 (0.71%)
    5 / 141 (3.55%)
         occurrences all number
    1
    2
    3
    3
    1
    5
    Infections and infestations
    Influenza
         subjects affected / exposed
    4 / 80 (5.00%)
    3 / 81 (3.70%)
    7 / 81 (8.64%)
    6 / 82 (7.32%)
    10 / 141 (7.09%)
    6 / 141 (4.26%)
         occurrences all number
    4
    5
    7
    6
    11
    6
    Sinusitis
         subjects affected / exposed
    3 / 80 (3.75%)
    4 / 81 (4.94%)
    3 / 81 (3.70%)
    2 / 82 (2.44%)
    2 / 141 (1.42%)
    0 / 141 (0.00%)
         occurrences all number
    6
    7
    3
    3
    2
    0
    Acute sinusitis
         subjects affected / exposed
    3 / 80 (3.75%)
    4 / 81 (4.94%)
    2 / 81 (2.47%)
    3 / 82 (3.66%)
    2 / 141 (1.42%)
    6 / 141 (4.26%)
         occurrences all number
    7
    6
    2
    3
    4
    8
    Bronchitis
         subjects affected / exposed
    3 / 80 (3.75%)
    8 / 81 (9.88%)
    6 / 81 (7.41%)
    3 / 82 (3.66%)
    13 / 141 (9.22%)
    9 / 141 (6.38%)
         occurrences all number
    4
    10
    8
    4
    20
    11
    Nasopharyngitis
         subjects affected / exposed
    8 / 80 (10.00%)
    11 / 81 (13.58%)
    7 / 81 (8.64%)
    13 / 82 (15.85%)
    5 / 141 (3.55%)
    13 / 141 (9.22%)
         occurrences all number
    13
    19
    13
    16
    6
    17
    Pharyngitis
         subjects affected / exposed
    3 / 80 (3.75%)
    8 / 81 (9.88%)
    3 / 81 (3.70%)
    7 / 82 (8.54%)
    5 / 141 (3.55%)
    6 / 141 (4.26%)
         occurrences all number
    3
    10
    3
    9
    5
    6
    Rhinitis
         subjects affected / exposed
    3 / 80 (3.75%)
    3 / 81 (3.70%)
    3 / 81 (3.70%)
    2 / 82 (2.44%)
    5 / 141 (3.55%)
    3 / 141 (2.13%)
         occurrences all number
    3
    3
    3
    3
    5
    7
    Upper respiratory tract
         subjects affected / exposed
    4 / 80 (5.00%)
    7 / 81 (8.64%)
    7 / 81 (8.64%)
    5 / 82 (6.10%)
    10 / 141 (7.09%)
    11 / 141 (7.80%)
         occurrences all number
    6
    12
    8
    6
    12
    14
    Urinary tract infection
         subjects affected / exposed
    4 / 80 (5.00%)
    2 / 81 (2.47%)
    1 / 81 (1.23%)
    3 / 82 (3.66%)
    5 / 141 (3.55%)
    3 / 141 (2.13%)
         occurrences all number
    4
    3
    1
    4
    5
    3

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    11 Apr 2011
    The exclusion criteria for mitigation of parasitic infection associated with eosinophil depletion due to benralizumab were modified. Added an exploratory objective to analyse the performance of different helminth serology assays. Exclusion criterion 1 was revised to exclude subjects with allergic bronchopulmonary aspergillosis from participation. Exclusion criterion 27 was revised to ensure subjects were able to perform spirometry during the study. Exclusion criterion 28 was added to exclude subjects who used any oral or ophthalmic β-adrenergic antagonist. Withdrawal criterion was added that a subject would be discontinued from further investigational product administration based on an AE as determined by the sponsor. Withdrawal criterion added that the development of S stercoralis in subjects with chronic OCS-dependent asthma. Schedule of study procedures: The hepatitis A antibody test was removed from screening. Added that unblinded staff must not administer investigational product to the subject to maintain the integrity of the study blind. Added Asthma Symptom Diary Anchoring Questions. Schedule of study procedures: Hepatitis A antibody test was removed from screening. Schedule of study procedures: An early discontinuation visit was added and added serology testing for S stercoralis in subjects with chronic oral corticosteroiddependent asthma at Weeks 16, 32, 52, and 66. Added 4-day window to Screening Visit. Added collection of time of administration of the first injection of investigational product. Added Early Discontinuation Visit for subjects who discontinued the study prematurely. Added footnote under list of serum chemistries to conduct and assess tests for AST, ALT, ALP, and total bilirubin concurrently. Added procedures for parasite serology testing of S stercoralis, and for collection and analysis of stool samples. Added section on hepatic function abnormality as a measure of safety. Changed interim analysis to primary analysis.
    14 Nov 2011
    Changed total number of subjects to be randomized to 522 and total number of EOS+ subjects to be randomized to 280; changed number of EOS+ subjects in each treatment regimen from 60 to 70. Changed number of months for expected enrollment to 15-18. Changed number of weeks that subjects should return to the study site for peripheral blood eosinophil counts to 8. Changed study-stopping reason to reflect the occurrence of confirmed immune complex disease in a subject treated with benralizumab. Changes in inclusion and exclusion criteria. Added that a major deviation from the study protocol as judged by the investigator and/or the sponsor a reason for withdrawal. Modified procedures for following subjects for safety who were permanently discontinued from receiving investigational product. Changed procedures to allow for replacement of subjects who had not met major eligibility criteria and were withdrawn after receiving at least one dose of investigational product in error. Specified 21-gauge needle to be used. Specified when investigational product should not be administered. Updated text describing medium and high doses of ICS/LABA combination inhalers; added that subjects on high-dose ICS/LABA who used a secondary ICS inhaler were to be classified as high-dose subjects. Text describing rescreening procedures was modified. Removed sentence and reference citation regarding minimally clinical important difference in the TNSS-3. Changed the significance level to 0.2; changed the two-sided confidence interval to 80%; changed the sample size of the eosinophil-positive cohort and provided justification to augment the probability that the primary objective of detecting a reduction in asthma exacerbations in active versus placebo with adequate statistical power will be achieved; updated references as needed.
    16 Jul 2012
    Added section describing potential reason for stopping study for futility. Added interim analysis and a section describing unblinding for the interim analysis. Changed references to Week 52 analysis to Stage I analysis; Clarified the Stage I and Stage II analyses that will be conducted. Changed the primary endpoint analysis from Cochran-Mantel-Haenszel method to Poisson regression with overdispersion adjustment factor. Cochran-Mantel- Haenszel and negative binomial regression were considered sensitivity analyses. Removed weighted mean rate of asthma exacerbations as an exploratory endpoint.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Apr 23 22:12:07 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA